CVS CVS HEALTH Corp Insider Trading

Director Larry Robbins sold 3,372,000 shares of CVS for $317,471,136.18 across 7 transactions (May 19-21, 2026), reducing holdings 41.1%.

Larry Robbins, a Director at CVS HEALTH, executed 7 separate sales totaling 3,372,000 shares for $317,471,136.18, reducing his post-transaction holdings to 4,824,799 shares (a net reduction of 41.1% vs pre-transaction holdings of 8,196,799 shares). The blended average sale price was $94.15 across transactions dated May 19–21, 2026, compared to the current price of $93.32, positioning these sales near recent market levels. Robbins' prior 5 sales at CVS were uniformly well-timed at the 90-day mark, with negative 90-day returns ranging from -5.0% to -8.1%, indicating a consistent pattern of selling ahead of subsequent price declines; his cross-ticker track record shows a 100% well-timed rate on 6 prior sells with an average 90-day return of -8.5%. This large, multi-transaction liquidation—while maintaining a substantial residual stake of 4.82M shares—is notable given his demonstrated historical success at timing CVS sales to precede market weakness.

CVS Chief Exp & Tech Officer Mandadi Tilak sells 87% of holdings in single transaction.

Mandadi Tilak, CVS's Chief Experience and Technology Officer, executed a substantial sale disposing of the majority of his holdings. This is his first open-market sale in the three-year period; his prior Form 4 activity consisted entirely of stock-based compensation transactions. The sale occurred as the stock trades at its 52-week high, having rallied significantly over the past three months. CVS remains a profitable company with growing revenue, though it trades at a relatively elevated valuation multiple. The timing of this large exit—coming from an executive with direct operational responsibility while the stock has recently strengthened—warrants attention as a potential signal of insider reassessment, though the singular nature of this trade and the absence of broader insider selling prevents a high-confidence interpretation.